Efficacy of a combined oral contraceptive containing 0.030mg ethinylestradiol/2mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035mg ethinylestradiol/2mg cyproterone acetate

The paper compares the efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for papulopustular acne, evaluating it against placebo and against another combined oral contraceptive containing 0.035 mg ethinylestradiol/2 mg cyproterone acetate. It reports comparative treatment effects for papulopustular acne across the study arms, focusing on whether the dienogest-containing formulation performs better than placebo and how it measures up to the cyproterone acetate comparator. A key limitation is that the provided text does not include details on study design, sample size, outcomes, or stated limitations beyond the citation metadata. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works